Why the study?
AAV gene therapy carrying microdystrophin was recently FDA-approved for DMD, but its impact on respiratory function remains unclear.
Does systemic administration of AAV-cc47-μDys improve respiratory function and muscle integrity in the mdx mouse model of Duchenne Muscular Dystrophy?
Does systemic administration of AAV-cc47-μDys improve respiratory function and muscle integrity in the mdx mouse model of Duchenne Muscular Dystrophy?
AAV-cc47-μDys gene therapy provides partial long-term improvement in respiratory function and diaphragm muscle integrity in a mouse model of Duchenne Muscular Dystrophy.
Answers are grounded in this paper and cite their sources.
May support respiratory benefits of AAV microdystrophin in DMD models; leaves open translation to patients pending human trials.
Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder caused by the absence of functional dystrophin, leading to progressive muscle degeneration, respiratory insufficiency, and ultimately cardiorespiratory failure. Adeno-associated viral (AAV) gene therapy carrying microdystrophin (μDys) was recently FDA approval for DMD, but its impact on respiratory function remains unclear. The goal of this study is to evaluate the therapeutic potential of AAV-cc47, an engineered AAV9-based capsid with enhanced cross-species transduction efficiency, delivering μDys in the mdx mouse model of DMD. The mice received systemic administration of AAV-cc47-μDys at 2mo of age and were assessed bi-monthly for respiratory function using whole-body plethysmography under normoxic (FiO 2 : 0.21; N 2 balance) and hypoxic–hypercapnic (FiCO 2 : 0.07, FiO 2 : 0.10; N 2 balance) conditions, followed by terminal pulmonary mechanics evaluation via forced oscillation. Postmortem analyses were performed at 4mo and 12mo to assess short- and long-term treatment effects. The earlier time point showed no significant differences with therapy, however assessment at 12mo showed partial but significant enhancements in minute ventilation, peak inspiratory and expiratory flow along with overall pulmonary mechanics. Postmortem analysis showed ubiquitous distribution of vector genomes throughout the body, and an increase of dystrophin expression and decreased inflammation in the diaphragm of AAV-cc47-μDys-treated mdx mice. AAV-cc47-μDys treatment slightly improves respiratory function and muscle integrity but does not result in complete correction of DMD pathology. Funding: NHLBI R01HL171282 (MKE) This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2026) studied Duchenne Muscular Dystrophy (DMD). AAV-cc47-μDys was evaluated on Respiratory function and pulmonary mechanics.
Synapse has enriched 10 related papers. Consider them for comparative context: